A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)

Authors
Category Primary study
Registry of TrialsAustralian New Zealand Clinical Trials Register
Year 2014
This article has no abstract
Epistemonikos ID: 665208d866293d92cbbb4fad62ba004c31aa82a2
First added on: Jul 28, 2026